Mucocutaneous Hyperpigmentation Associated with Hydroxyurea Therapy in a Patient with Essential Thrombocythemia: Case Report

Introduction: Mucocutaneous hyperpigmentation is a dermatological condition that may be related to chemotherapy treatments, such as therapies using hydroxyurea (HU). HU is a cytostatic drug widely used in myeloproliferative diseases and is the main line of treatment for essential thrombocythemia (ET...

Descripción completa

Detalles Bibliográficos
Autores: Rodrigues, Daniela de Oliveira Werneck, Santos, Augusto Cézar Apolinário dos, Espósito, Thais Sette, Fonseca, Lucas Augusto Niess Soares, Mathiasi , Lucas Barra, Abreu, Nathália Chebli de, Costa , Monica de Albuquerque, Magalhães, Nathalia Noyma Sampaio, Fabri, Júlia Campos
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:Brasil
Institución:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
Repositorio:Revista Brasileira de Cancerologia (Online)
Idioma:portugués
inglés
español
OAI Identifier:oai:rbc.inca.gov.br:article/2995
Acceso en línea:https://rbc.inca.gov.br/index.php/revista/article/view/2995
Access Level:acceso abierto
Palabra clave:hiperpigmentação
hidroxiureia
trombocitemia essencial
hyperpigmentation
hydroxyurea
thrombocythemia, essential
hiperpigmentación
hidroxiurea
trombocitemia esencial
Descripción
Sumario:Introduction: Mucocutaneous hyperpigmentation is a dermatological condition that may be related to chemotherapy treatments, such as therapies using hydroxyurea (HU). HU is a cytostatic drug widely used in myeloproliferative diseases and is the main line of treatment for essential thrombocythemia (ET). The present study aims to report a rare case of mucocutaneous hyperpigmentation in a patient with ET. Case report: Male patient, 68 years old, 89 kg, diagnosed with ET using HU 2 g/day. After three months of therapy, he presented hyperpigmented brownish-colored lesions on the hands and oral cavity (tongue). In a decision shared with the assistant physician, the patient chose to continue using the drug. After six years of follow-up, the lesions remain stable. Conclusion: Mucocutaneous hyperpigmentation associated with HU therapy is a benign event secondary to the use of the drug and does not require discontinuation of use, however, its withdrawal or dose reduction usually leads to the reduction or disappearance of the lesions.